Wegovy reduces knee pain in osteoarthritis patients with obesity, study finds

Semaglutide, better known as Ozempic and Wegovy, helped alleviate pain from knee osteoarthritis and improve function in patients with severe obesity, a new study found.

The results of the 68-week trial were published in the New England Journal of Medicine, and could pave the way for a future FDA approval of GLP-1 receptor agonists for the joint-degrading condition.

GLP-1 drugs have revolutionized obesity treatment, but research suggests they could also help treat conditions as varied as heart disease, addiction and sleep apnea. Novo Nordisk, the maker of Wegovy, may have funded the latest trial to see if knee osteoarthritis might be added to that growing list of non-obesity indications — and help the drug get broader insurance coverage.

STAT+ Exclusive Story

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

WHO declares mpox outbreak a global health emergency

The World Health Organization on Wednesday declared the spread of mpox in multiple African countries a public health emergency of international concern, the second such

August 14, 2024

Study offers insights into who’s at risk for long COVID among immunocompromised patients

Early in the pandemic, clinicians noticed that certain immunocompromised patients were experiencing persistent SARS-CoV-2 infections, some lasting weeks to months at a time.

January 27, 2024

Heat-related mortality in Europe may have exceeded 70,000 in 2022

The burden of heat-related mortality during the summer of 2022 in Europe may have exceeded 70,000 deaths according to a study led by the Barcelona

November 21, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.